Sara Spettel Aliyar, MD
Urology · Portland, ORNPI 1750544243
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 59 manufacturers reported payments, led by AbbVie at 54.2% of the total. Reporting peaked in 2019 at $6,061 and has fallen 56.5% since, to $2,637 in 2025. Among urology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 511 payments — averaging $40.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Astellas Pharma US Inc$1K
- Sumitomo Pharma America, Inc.$708
- Boston Scientific$689
- Johnson & Johnson$611
- Dendreon Pharmaceuticals LLC$521
- plus $6K from 53 others
What the payments were for
- Speaking & faculty fees$8,80042%
- Travel & lodging$8464%
- Food & beverage$11,15253%
- Education$970%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$9,790
- REZUM$243
- GEMTESA$219
- Dornier MedTech$143
- Porges Coloplast$133
- RYBREVANT$122
- CARVYKTI$122
How this compares
$20,894 in reported general payments places this provider in the 90th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 33 | $33,076 |
| MyrbetriqMirabegron | 47 | $26,324 |
| Estradiol | 217 | $14,440 |
| Tamsulosin Hcl | 947 | $9,588 |
| NitrofurantoinNitrofurantoin Macrocrystal | 275 | $7,096 |
| Finasteride | 661 | $6,447 |
| Solifenacin Succinate | 268 | $5,413 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $1,455 |
| Cephalexin | 122 | $1,237 |
| Oxybutynin Chloride ErOxybutynin Chloride | 38 | $587 |
| Trimethoprim | 21 | $503 |
| Oxybutynin Chloride | 48 | $499 |
| Sodium ChlorideSodium Chloride Irrig Solution | 19 | $241 |
| Oxycodone Hcl | 38 | $192 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $708 | $33,07633 claims |
| Astellas Pharma US IncMyrbetriq | $1,037 | $26,32447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 153 urology providers in Oregon.
Other urology in Portland
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Amir PatelPortland$36K
- James TycastPortland$35K
- Sudhir IsharwalPortland$30K
- Ian MetzlerPortland$23K
- Daniel JanoffPortland$15K
- James BreseePortland$14K
- Stanley MyersPortland$11K
- Sajal DuttaPortland$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.